US4910015A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Surface-active polysiloxanes and drug releasing materials thereof
Assignee: Massachusetts Institute of Technology
•
Filing: 1987-10-19
•
Granted: 1990-03-20
•
Expires: 2007-10-19
Abstract
Abstract A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a polyglycidoxypropylsiloxane is described. These materials form hydrogel networks having very high partition coefficients for selected pharmaceuticals and are suitable for controlled drug release and water purification.
Inventors
- 👤 Cynthia Sung
- 👤 Edward W. Merrill
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 02:29
CPC Classifications
C; C08; C08G; C08G77/00; C08G77/42; C08G77/46; A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/2036; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0017; A61L33/06; A61L33/068; C02; C02F; C02F1/00; C02F1/28; C02F1/285
Claims Analysis
Total Claims: 44
Claim 1
Independent Claim
24 words
A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a glycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule.
Claim 2
Dependent Claim
24 words
A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a glycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule.
Claim 3
Dependent Claim
16 words
A crosslinked polymer network as in claim 1 further having a pharmaceutical incorporated into the network.
Claim 4
Dependent Claim
15 words
A crosslinked polymer network as in claim 2 wherein the pharmaceutical is a tricyclic antidepressant.
Claim 5
Dependent Claim
25 words
A crosslinked polymer network as in claim 3 wherein the tricyclic antidepressant is selected from the group consisting of protriptyline, amitriptyline, trimipramine, imipramine, and desipramine.
Claim 6
Dependent Claim
16 words
A crosslinked polymer network as in claim 2 wherein the pharmaceutical is leutinizing hormone release hormone.
Claim 7
Dependent Claim
13 words
A crosslinked polymer network as in claim 1 wherein the glycidoxypropylsiloxane is polyglycidoxypropylmethylsiloxane.
Claim 8
Dependent Claim
15 words
A crosslinked polymer network as in claim 1 wherein the glycidoxypropylsiloxane is a poly(glycidoxypropylmethlysiloxane/dimethylsiloxane) copolymer.
Claim 9
Dependent Claim
37 words
A crosslinked polymer network as in claim 1 wherein the polyethylene oxide is selected from the group consisting of dihydroxy polyethylene oxide, polyethylene glycol monomethyl ether, polyethylene glycol monothyl ether, monoamino polyethylene oxide, and diamino polyethylene oxide.
Claim 10
Dependent Claim
86 words
A crosslinked polymer network comprising a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule crosslinked with polyethylene oxide, produced by the method comprising the steps of: (a) mixing polyethylene oxide and a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule in solvent to form a reaction mixture; (b) adding a Lewis acid catalyst to the reaction mixture; (c) allowing the mixture to react to form a crosslinked network; and, (d) removing solvent from the product, thereby producing a crosslinked polyethylene oxide/polyglycidoxypropylsiloxane material.
Claim 11
Dependent Claim
86 words
A crosslinked polymer network comprising a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule crosslinked with polyethylene oxide, produced by the method comprising the steps of: (a) mixing polyethylene oxide and a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule in solvent to form a reaction mixture; (b) adding a Lewis acid catalyst to the reaction mixture; (c) allowing the mixture to react to form a crosslinked network; and, (d) removing solvent from the product, thereby producing a crosslinked polyethylene oxide/polyglycidoxypropylsiloxane material.
Claim 12
Dependent Claim
12 words
A polymer network as in claim 9 wherein the polyglycdoxypropylsiloxane is polyglycidoxypropylmethylsiloxane.
Claim 13
Dependent Claim
13 words
A polymer network as in claim 9 wherein the polyglycidoxypropylsiloxane is poly(glycidoxypropylmethlsiloxane/dimethysiloxane) copolymer.
Claim 14
Dependent Claim
30 words
A polymer network as in claim 9 wherein the polyethylene oxide is selected from the group consisting of dihydroxy polyethylene oxide, polyethylene glycol monomethyl ether and polyethylene glycol monoethyl ether.
Claim 15
Dependent Claim
12 words
A polymer network as in claim 9 wherein the solvent is dichloromethane.
Claim 16
Dependent Claim
38 words
A polymer network as in claim 9 wherein the Lewis acid catalyst is selected from the group consisting of BF 3 , BC 3 , AlCl 3 , SbF 3 , SbF 5 , and SbCl 5 .
Claim 17
Dependent Claim
18 words
A polymer network as in claim 9 wherein the solvent is removed from the product polymer by drying.
Claim 18
Dependent Claim
96 words
A crosslinked polymer network comprising a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypopyl units per molecule crosslinked with a polyethylene oxide selected from the group consisting of monoamino polyethylene oxide and diamino polyethylene oxide, the crosslinked polymer network produced by the method comprising: (a) mixing the polyethylene oxide and polyglydicoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule in solvent to form a reaction mixture; (b) heating the reaction mixture; (c) allowing the mixture t react to form a cross-linked network; and, (d) removing solvent from the product, thereby producing a crosslinked polyethylene oxide/polyglycidoxypropylsiloxane material.
Claim 19
Dependent Claim
96 words
A crosslinked polymer network comprising a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypopyl units per molecule crosslinked with a polyethylene oxide selected from the group consisting of monoamino polyethylene oxide and diamino polyethylene oxide, the crosslinked polymer network produced by the method comprising: (a) mixing the polyethylene oxide and polyglydicoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule in solvent to form a reaction mixture; (b) heating the reaction mixture; (c) allowing the mixture t react to form a cross-linked network; and, (d) removing solvent from the product, thereby producing a crosslinked polyethylene oxide/polyglycidoxypropylsiloxane material.
Claim 20
Dependent Claim
12 words
A polymer network as in claim 16 wherein the polyglycidoxypropylsiloxane is polyglycidoxypropylmethylsiloxane.
Claim 21
Dependent Claim
13 words
A polymer network as in claim 16 wherein the polyglycidoxypropylsiloxane is poy(glydicoxypropylmethylsiloxane/dimethysiloxane) copolymer.
Claim 22
Dependent Claim
12 words
A polymer network as in claim 16 wherein the solvent is toluene.
Claim 23
Dependent Claim
20 words
A polymer network as in claim 16 wherein the reaction mixture is heated to a temperature of about 35° C.
Claim 24
Dependent Claim
15 words
A polymer network as in claim 16 wherein the solvent is remove by vacuum drying.
Claim 25
Independent Claim
86 words
A method for the controlled release of pharmaceuticals comprising the steps of: (a) providing a crosslinked polyethylene oxidepolyglycidoxypropylsiloxane network wherein the polyglycidoxypropylsiloxane is poly glycidoxypropylmethylsiloxane having between 3 and 25 glycidoxypropyl units per molecule, (b) contacting the crosslinked network with a solution containing a pharmaceutical; (c) allowing the pharmaceutical to incorporate into the crosslinked network; (d) contacting the pharmaceutical-containing network with the body fluids of a patient; and, (e) allowing the pharmaceutical-containing network to release the pharmaceutical into the patient over an extended period of time.
Claim 26
Independent Claim
86 words
A method for the controlled release of pharmaceuticals comprising the steps of: (a) providing a crosslinked polyethylene oxidepolyglycidoxypropylsiloxane network wherein the polyglycidoxypropylsiloxane is poly glycidoxypropylmethylsiloxane having between 3 and 25 glycidoxypropyl units per molecule, (b) contacting the crosslinked network with a solution containing a pharmaceutical; (c) allowing the pharmaceutical to incorporate into the crosslinked network; (d) contacting the pharmaceutical-containing network with the body fluids of a patient; and, (e) allowing the pharmaceutical-containing network to release the pharmaceutical into the patient over an extended period of time.
Claim 27
Dependent Claim
21 words
A method as in claim 26 wherein the polyglycidoxypropylsiloxane is poly(glycidoxypropylmethylsiloxane/dimethylsiloxane) copolymer having between 3 and 25 glycidoxypropyl units per molecule.
Claim 28
Dependent Claim
35 words
A method as in claim 22 wherein the polyethylene oxide is selected from tee group consisting of dihydroxy polyethylene oxide, polyethylene glycol monomethyl ether, polyethylene glycol monoethyl ether, monoamino polyethylene oxide and diamino polyethylene oxide.
Claim 29
Dependent Claim
13 words
A method as in claim 22 wherein the pharmaceutical is a tricyclic antidepressant.
Claim 30
Dependent Claim
23 words
A method as in claim 25 wherein the tricyclic antidepressant is selected from the group consisting of protriptyline, amitriptyline, trimipramine, imipramine and desipramine.
Claim 31
Dependent Claim
14 words
A method as in claim 22 wherein the pharmaceutical is leutinizing hormone release hormone.
Claim 32
Dependent Claim
25 words
A hydrogel comprising an aqueous solution and the reaction product of polyethylene oxide and a glycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule.
Claim 33
Dependent Claim
25 words
A hydrogel comprising an aqueous solution and the reaction product of polyethylene oxide and a glycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule.
Claim 34
Dependent Claim
13 words
A hydrogel as in claim 28 wherein the aqueous solution contains a pharmaceutical.
Claim 35
Dependent Claim
13 words
A hydrogel as in claim 28 wherein the pharmaceutical is a tricyclic antidepressant.
Claim 36
Dependent Claim
23 words
A hydrogel as in claim 28 wherein the tricyclic antidepressant is selected from the group consisting of protriptyline, amitriptyline, trimipramine, imipramine, and desipramine.
Claim 37
Dependent Claim
14 words
A hydrogel as in claim 28 wherein the pharmaceutical is leutinizing hormone release hormone.
Claim 38
Dependent Claim
11 words
A hydrogel as in claim 28 wherein the glycidoxypropylsiloxane is polyglycidoxypropylmethylsiloxane.
Claim 39
Dependent Claim
13 words
A hydrogel as in claim 28 wherenn the glycidoxypropylsiloxane is a poly(glycidoxypropylmethylsiloxane/dimethylsiloxane) copolymer.
Claim 40
Dependent Claim
35 words
A hydrogel as in claim 28 wherein the polyethylene oxide is selected from the group consisting of dihydroxy polyethylene oxide, polyethylene glycol monomethyl ether, polyethylene glycol monoethyl ether, monoamino polyethylene oxide, and diamino polyethylene oxide.
Claim 41
Dependent Claim
20 words
The emulsion produced by contacting a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule with an aqueous solution.
Claim 42
Dependent Claim
20 words
The emulsion produced by contacting a polyglycidoxypropylsiloxane having between 3 and 25 glycidoxypropyl units per molecule with an aqueous solution.
Claim 43
Dependent Claim
25 words
A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a polyglycidoxypropylsiloxane having between about 3 and 25 glycidoxypropyl units per molecule.
Claim 44
Dependent Claim
25 words
A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a polyglycidoxypropylsiloxane having between about 3 and 25 glycidoxypropyl units per molecule.
References Cited (Backward Citations)
EP0002519A1
Cited
US4675361A
Cited
US4686137A
Cited
US4423099A
Cited
US4548990A
Cited
US4624848A
Cited
US4625010A
Cited
US4666745A
Cited
US4684709A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-19 | 1993-09-18 | 1994-03-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-19 | 1997-09-18 | 1998-03-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-19 | 2001-09-18 | 2002-03-20 | $7700.00 | Window Closed / Lapsed |